Results 51 to 60 of about 185,596 (291)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective

The Journal of Liquid Biopsy
Although there have been significant advances in the early detection and treatment of gallbladder cancer (GBC), it is still considered a leading cause of morbidity and mortality. Molecular profiling of tumors is generally performed using samples obtained
Sridhar Mishra, Swati Kumari, Nuzhat Husain   +2 more
doaj   +1 more source

Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges

, 2017
Tumor heterogeneity in hepatocellular carcinoma (HCC), such as that found in second primary tumors after curative treatment, synchronous multifocal tumors of different clonality, or intratumor heterogeneity, poses severe challenges for the development ...
鄭安理;徐志宏;許駿;呂理駿, Lu, Li-Chun;Hsu, Chih-Hung;Hsu, Chiun;Cheng, Ann-Lii   +1 more
core   +1 more source

promoter mutations in circulating tumor DNA [PDF]

, 2020
Background and Aim Human telomerase reverse transcriptase (TERT) promoter mutations were the most prevalent mutations in patients with hepatocellular carcinoma (HCC).
Yamamoto, Shumpei, Okada, Hiroyuki, Kinugasa, Hideaki, Atsushi Oyama, Hiroyuki Okada, Hiroyuki Terasawa, Onishi, Hideki, Wada, Nozomu, Masahiro Sakata, Hideki Onishi, Adachi, Takuya, Oyama, Atsushi, Mami Hirai, Akinobu Takaki, Takaki, Akinobu, Nouso, Kazuhiro, Yuma Onishi, Takuya Adachi, Yasunaka, Tetsuya, Nozomu Wada, Hidenori Shiraha, Shiraha, Hidenori, Terasawa, Hiroyuki, Onishi, Yuma, Sakata, Masahiro, Hirai, Mami, Kazuhiro Nouso, Shumpei Yamamoto, Hideaki Kinugasa, Tetsuya Yasunaka   +29 more
core   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Liquid-based biomarkers in breast cancer: looking beyond the blood

Journal of Translational Medicine, 2023
In recent decades, using circulating tumor cell (CTC), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), exosomes and etc. as liquid biomarkers has received enormous attention in various tumors, including breast cancer (BC).
You Shuai, Zhonghua Ma, Jie Ju, Tong Wei, Songlin Gao, Yikun Kang, Zixuan Yang, Xue Wang, Jian Yue, Peng Yuan   +9 more
doaj   +1 more source

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer [PDF]

Molecular Oncology, 2016
Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type and is characterized by a dismal prognosis due to late diagnosis, local tumor invasion, frequent distant metastases and poor sensitivity to current therapy. In this context, circulating tumor cells and circulating tumor DNA constitute easily accessible blood‐borne tumor
Riva, Francesca; Dronov, Oleksii I.; Khomenko, Dmytro I.; Huguet, Florence; Louvet, Christophe; Mariani, Pascale; Stern, Marc-Henri; Lantz, Olivier; Proudhon, Charlotte; Pierga, Jean-yves; Bidard, Francois-Clement   +11 more
openaire   +2 more sources

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types

, 2017
Cancer is a disease of complex genetic alterations, and comprehensive genetic diagnosis is beneficial to match each patient to appropriate therapy. However, acquisition of representative tumor samples is invasive and sometimes impossible.
Chen, XF, Wang, ZX, Liang, Y, Zhu, CR, Mao, Y, Shao, HW, Shu, YQ, Hong, Z, Shao, YW (reprint author), Geneseeq Technol Inc, Toronto, ON, Canada., Chang, ZL, Sun, J, Chen, J, Shao, YW, Tong, XL, Zhu, LJ, Wu, X, Wang, XN   +16 more
core   +1 more source